The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety

References

• Ahmed, S. H. 2005. Imbalance between drug and non-drug reward availability: A major risk factor for addiction. European Journal of Pharmacology 526:9–20. doi:10.1016/j.ejphar.2005.09.036.
   PubMed Web of Science ®Google Scholar
• Bachtella, R. K., J. D. Jones, C. G. Heinzerling, P. M. Beardsley, and S. D. Comer. 2017. Glial and neuroinflammatory targets for treating substance use disorders. Drug and Alcohol Dependence 180:156–70. doi:10.1016/j.drugalcdep.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Bland, S. T., M. R. Hutchinson, and S. F. Maier. 2009. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain, Behavior, and Immunity 23:492–97. doi:10.1016/j.bbi.2009.01.014.
   PubMed Web of Science ®Google Scholar
• Comer, S. D., E. D. Collins, and M. W. Fischman. 1997. Choice between money and intranasal heroin in morphine-maintained humans. Behavioural Pharmacology 8 (8):677–90.
   PubMed Web of Science ®Google Scholar
• Comer, S. D., E. D. Collins, R. B. MacArthur, and M. W. Fischman. 1999. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacol 143:327–38. doi:10.1007/s002130050956.
   Web of Science ®Google Scholar
• Comer, S.D., M.A. Sullivan, and E.A. Walker. 2005. Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. Journal Of Pharmacology and Experimental Therapeutics 315:1320–1330.
   PubMed Web of Science ®Google Scholar
• Cooper, Z. D., J. D. Jones, and S. D. Comer. 2012. Glial Inhibitors: A novel pharmacological approach to modulating the behavioral effects of abused substances. Expert Opinion Investigations Drugs 21:169–78. doi:10.1517/13543784.2012.651123.
   PubMed Web of Science ®Google Scholar
• Cooper, Z. D., K. W. Johnson, M. Pavlicova, A. Glass, S. K. Vosburg, M. A. Sullivan, J. M. Manubay, D. M. Martinez, J. D. Jones, P. A. Saccone, and S. D. Comer. 2016. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addiction Biology 21 (4):895–903. doi:10.1111/adb.12261.
   PubMed Web of Science ®Google Scholar
• de Guglielmo, G., M. Kallupi, G. Scuppa, G. Demopulos, Gaitanaris, and R. Ciccocioppo. 2017. Pioglitazone attenuates the opioid withdrawal syndrome and reduces the vulnerability to relapse to heroin seeking. Psychopharmacology 234:223–34. doi:10.1007/s00213-016-4452-1.
   PubMed Web of Science ®Google Scholar
• de Guglielmo, G., M. Kallupi, G. Scuppa, S. Stopponi, G. Demopulos, G. Gaitanaris, and R. Ciccocioppo. 2014. Analgesic tolerance to morphine is regulated by PPARγ. British Journal of Pharmacology 171 (23):5407–16. doi:10.1111/bph.12851.
   PubMed Web of Science ®Google Scholar
• de Guglielmo, G., M. Melis, M. A. de Luca, M. Kallupi, H. W. Li, K. Niswender, and A. Giordano. 2015. PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. Neuropsychopharmacol 40:927–37. doi:10.1038/npp.2014.268.
   PubMed Web of Science ®Google Scholar
• Eidson, L. N., and A. Z. Murphy. 2013. Blockade of Toll-like receptor 4 attenuates morphine tolerance and facilitates the pain relieving properties of morphine. The Journal of Neuroscience 33:15952–63. doi:10.1523/JNEUROSCI.1609-13.2013.
   PubMed Web of Science ®Google Scholar
• Eisenstein, T. K. 2011. Opioids and the immune system: What is their mechanism of action? British Journal of Pharmacology 164:1826–28. doi:10.1111/j.1476-5381.2011.01513.x.
   PubMed Web of Science ®Google Scholar
• Eisenstein, T. K., M. E. Hilburger, and D. M. P. Lawrence. 1996. Immunomodulation by morphine and other opioids. In Drugs of abuse, immunity and infections, ed. H. Friedman, T. W. Klein, and S. Specter, 103–20. Boca Raton: CRC Press.
   Google Scholar
• Eisenstein, T. K., R. T. Rahim, P. Feng, N. K. Thingalaya, and J. J. Meissler. 2006. Effects of opioid tolerance and withdrawal on the immune system. Journal of Neuroimmune Pharmacology 1:237–49. doi:10.1007/s11481-006-9019-1.
   PubMed Web of Science ®Google Scholar
• Ferguson, L. B., D. Most, Y. A. Blednov, and R. A. Harris. 2014. PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption. Neuropharmacology 86:397–407. doi:10.1016/j.neuropharm.2014.06.024.
   PubMed Web of Science ®Google Scholar
• Foltin, R. W., M. Haney, E. Rubin, S. C. Reed, N. Vadhan, R. Balter, and S. M. Evans. 2015. Development of translational preclinical models in substance abuse: Effects of cocaine administration on cocaine choice in humans and non-human primates. Pharmacology, Biochemistry, and Behavior 134:12–21. doi:10.1016/j.pbb.2015.03.023.
   PubMed Web of Science ®Google Scholar
• Gagnon, J., J. M. Roth, M. Carroll, K. A. Haycock, J. Plamondon, D. S. Feldman, and J. Simpson. 1990. Superanova accessible general linear modeling. Yale Journal of Biology and Medicine 63:191–92.
   Web of Science ®Google Scholar
• Gillies, P. S., and C. J. Dunn. 2000. Pioglitazone. Drugs 60 (2):333–43.
   PubMed Web of Science ®Google Scholar
• Handelsman, L., K. J. Cochrane, M. J. Aronson, R. Ness, K. J. Rubinstein, and P. D. Kanof. 1987. Two new rating scales for opiate withdrawal. The American Journal of Drug and Alcohol Abuse 13:293–308. doi:10.3109/00952998709001515.
   PubMed Web of Science ®Google Scholar
• Haney, M., and R. Spealman. 2008. Controversies in translational research: Drug self-administration. Psychopharmacology (Berl) 199 (3):403–19. doi:10.1007/s00213-008-1079-x.
   PubMed Web of Science ®Google Scholar
• Hopkins, S. J., C. J. McMahon, N. Singh, J. Galea, M. Hoadley, S. Scarth, H. Patel, A. Vail, S. Hulme, N. J. Rothwell, A. T. King, and P. J. Tyrrell. 2012. Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection. Journal of Neuroinflammation 9:255–64. doi:10.1186/1742-2094-9-255.
   PubMed Web of Science ®Google Scholar
• Hutchinson, M. R., and L. R. Watkins. 2014. Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacolo 76:218–27. doi:10.1016/j.neuropharm.2013.05.039.
   PubMed Web of Science ®Google Scholar
• Hutchinson, M. R., S. S. Lewis, B. D. Coats, D. A. Skyba, N. Y. Crysdale, D. L. Berkelhammer, A. Brzeski, A. Northcutt, C. M. Vietz, C. M. Judd, S. F. Maier, L. R. Watkins, and K. W. Johnson. 2009. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain, Behavior, and Immunity 23:240–50. doi:10.1016/j.bbi.2008.09.012.
   PubMed Web of Science ®Google Scholar
• Hutchinson, M. R., S. S. Lewis, B. D. Coats, N. Rezvani, Y. Zhang, J. L. Wieseler, A. A. Somogyi, H. Yin, S. F. Maier, K. C. Rice, and L. R. Watkins. 2010. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers caus-es spinal proinflammation and related behavioral consequences. Neuroscience 167:880–93. doi:10.1016/j.neuroscience.2010.02.011.
   PubMed Web of Science ®Google Scholar
• Hutchinson, M. R., S. T. Bland, K. W. Johnson, K. C. Rice, S. F. Maier, and L. R. Watkins. 2007. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence and reward. Scientific World Journal 7:98–111. doi:10.1100/tsw.2007.230.
   Google Scholar
• Jacobsen, J. H. W., L. R. Watkins, and M. R. Hutchinson. 2014. Discovery of a novel site of opioid action at the innate immune pattern-recognition receptor TLR4 and its role in addiction. International Review of Neurobiology 118:129–63. doi:10.1016/B978-0-12-801284-0.00006-3.
   PubMed Web of Science ®Google Scholar
• Jones, J. D., M. A. Sullivan, J. Manubay, V. Metz, S. Mogali, and S. D. Comer. 2016. The effects of pioglitazone, a PPARγ receptor agonist, on the abuse liability of oxycodone. Physiology and Behavior 159:33–39. doi:10.1016/j.physbeh.2015.10.006.
   PubMed Web of Science ®Google Scholar
• Jones, J. D., S. D. Comer, V. E. Metz, J. M. Manubay, S. Mogali, R. Ciccocioppo, S. Martinez, M. Mumtaz, and A. Bisaga. 2017. Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. Pharmacology, Biochemistry & Behavior 163:90–100. doi:10.1016/j.pbb.2017.10.002.
   PubMed Web of Science ®Google Scholar
• Kielian, T., and P. D. Drew. 2003. Effects of PPARy agonists on central nervous system inflammation. Journal of Neuroscience Research 71:315–25. doi:10.1002/jnr.10494.
   PubMed Web of Science ®Google Scholar
• Koob, G. F., K. Lloyd, and B. Mason. 2009. Development of pharmacotherapies for drug addiction: A Rosetta Stone approach. Nature Reviews. Drug Discovery 8 (6):500–15. doi:10.1038/nrd2828.
   PubMed Web of Science ®Google Scholar
• Ledeboer, A., E. M. Sloane, E. D. Milligan, M. G. Frank, J. H. Mahony, S. F. Maier, and L. R. Watkins. 2005. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 115:71–83. doi:10.1016/j.pain.2005.02.009.
   PubMed Web of Science ®Google Scholar
• Ledeboer, A., T. Liu, J. A. Shumilla, J. H. Mahoney, S. Vijay, M. I. Gross, J. A. Vargas, L. Sultzbaugh, M. D. Claypool, L. M. Sanftner, L. R. Watkins, and K. W. Johnson. 2006. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biology 2:279–91. doi:10.1017/S1740925X0700035X.
   PubMedGoogle Scholar
• Liang, Y., H. Chu, Y. Jiang, and L. Yuan. 2016. Morphine enhances IL-1β release through toll-like receptor 4-mediated endocytic pathway in microglia. Purinergic Signalling 12:637–45. doi:10.1007/s11302-016-9525-4.
   PubMed Web of Science ®Google Scholar
• Mello, M. K., and S. S. Negus. 1996. Preclinical evaluation of pharmocotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacol 14:375–424. doi:10.1016/0893-133X(95)00274-H.
   PubMed Web of Science ®Google Scholar
• Mendes, W. B. 2009. Assessing autonomic nervous system activity. In Methods in social neuroscience, ed. E. Harmon-Jones, and J. Beer. New York, NY: Guilford Press.
   Google Scholar
• Moore, T. M., A. Seavey, K. Ritter, J. K. McNulty, K. C. Gordon, and G. L. Stuart. 2013. Eco-logical momentary assessment of the effects of craving and affect on risk for relapse during substance abuse treatment. Psychology of Addictive Behaviors 28:619–24. doi:10.1037/a0034127.
   PubMed Web of Science ®Google Scholar
• Narita, M., M. Miyatake, M. Narita, M. Shibasaki, K. Shindo, A. Nakamura, N. Kuzumaki, Y. Nagumo, and T. Suzuki. 2006. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacol 31:2476–88. doi:10.1038/sj.npp.1301007.
   PubMed Web of Science ®Google Scholar
• Pfützner, A., C.A. Schneider, and T. Forst. 2006. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Review Of Cardiovascular Therapy 4:445-459.
   PubMedGoogle Scholar
• Preller, K. H., M. Wagner, C. Sulzbach, K. Hoenig, J. Neubauer, P. E. Franke, N. Petrovsky, I. Frommann, A. K. Rehme, and B. B. Quednow. 2013. Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. European Neuropsychopharmacology 23 (10):1270–79. doi:10.1016/j.euroneuro.2012.11.007.
   PubMed Web of Science ®Google Scholar
• Rook, E. J., J. M. van Ree, W. van den Brink, M. J. Hillebrand, A. D. Huitema, V. M. Hendriks, and J. H. Beijnen. 2006. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic & Clinical Pharmacology & Toxicology 98 (1):86–96. doi:10.1111/j.1742-7843.2006.pto_233.x.
   PubMed Web of Science ®Google Scholar
• Spielberger, C. D., G. Jacobs, F. Russel, and R. Crane. 1983. Assessment of anger: The State-Trait Anger Scale. In Advances in personality assessment, ed. J. N. Butcher, and C. D. Spielberger, vol. 3, 112–34. Hillsdale, NJ: Lawrence Erlbaum Associates.
   Google Scholar
• SPSS I. 2009. SPSS 18.0.0 for windows. Chicago, IL, SPSS Inc.
   Google Scholar
• Stopponi, S., G. de Guglielmo, L. Somaini, A. Cippitelli, N. Cannella, M. Kallupi, M. Ubaldi, M. Heilig, G. Demopulos, G. Gaitanaris, and R. Ciccocioppo. 2013. Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. Alcoholism, Clinical and Experimental Research 37:1351–60. doi:10.1111/acer.12091.
   PubMed Web of Science ®Google Scholar
• Stopponi, S., L. Somaini, A. Cippitelli, N. Cannella, S. Braconi, M. Kallupi, B. Ruggeri, M. Heilig, G. Demopulos, G. Gaitanaris, M. Massi, and R. Ciccocioppo. 2011. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biological Psychiatry 69:642–49. doi:10.1016/j.biopsych.2010.12.010.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. 2014. National survey of substance abuse treatment services. Data on substance abuse treatment facilities. Rockville MD: US Department of Health and Human Services, DHHS Publication SMA 05–4112.
   Google Scholar
• Suzumura, A., A. Ito, M. Yoshikawa, and M. Sawada. 1999. Ibudilast suppresses tnf-alpha production by glial cells functioning mainly as type iii phosphodiesterase inhibitor in the cns. Brain Research 837:203–12. doi: 10.1016/S0006-8993(99)01666-2.
   PubMed Web of Science ®Google Scholar
• Sweitzer, S., and J. De Leo. 2011. Propentofylline: Glial modulation, neuroprotection, and alleviation of chronic pain. Handbook of Experimental Pharmacology 200:235–50.
   Google Scholar
• Theberge, F. R., X. Li, S. Kambhampati, C. L. Pickens, R. St Laurent, J. M. Bossert, M. H. Baumann, M. R. Hutchinson, K. C. Rice, L. R. Watkins, and Y. Shaham. 2013. Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biological Psychiatry 73:729–37. doi:10.1016/j.biopsych.2012.12.019.
   PubMed Web of Science ®Google Scholar
• Tiffany, S. T., and D. J. Drobes. 1991. The development and initial validation of a questionnaire on smoking urges. British Journal of Addiction 86:1467–76.
   PubMedGoogle Scholar
• Tiffany, S. T., E. Singleton, C. A. Haertzen, and J. E. Henningfield. 1993. The development of a cocaine craving questionnaire. Drug and Alcohol Dependence 34:19–28.
   PubMed Web of Science ®Google Scholar
• Tikka, T., B. L. Fiebich, G. Goldsteins, R. Keinanen, and J. Koistinaho. 2001. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. The Journal of Neuroscience 21 (8):2580–88.
   PubMed Web of Science ®Google Scholar
• Tsui, J. I., B. J. Anderson, D. R. Strong, and M. D. Stein. 2014. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: A longitudinal study. The American Journal of Drug and Alcohol Abuse 40 (2):163–69. doi:10.3109/00952990.2013.848875.
   PubMed Web of Science ®Google Scholar
• Wang, X., L. C. Loram, K. Ramos, A. J. de Jesus, J. Thomas, K. Cheng, A. Reddy, A. A. Somogyi, M. R. Hutchinson, L. R. Watkins, and H. Yin. 2012. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proceedings National Academic Sciences USA 109:6325–30. doi:10.1073/pnas.1200130109.
   PubMed Web of Science ®Google Scholar
• Watkins, L. R., M. R. Hutchinson, K. C. Rice, and S. F. Maier. 2009. The “toll” of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends in Pharmacological Sciences 30:581–91. doi:10.1016/j.tips.2009.08.002.
   PubMed Web of Science ®Google Scholar
• Watkins, L.R., M.R. Hutchinson, I.N. Johnston, and S.F. Maier. 2005. Glia: novel counter-regulators of opioid analgesia. Trends Neuroscience 28:661-669.
   PubMed Web of Science ®Google Scholar
• Weiss, R. D., M. L. Griffin, C. Mazurick, B. Berkman, D. R. Gastfriend, A. Frank, J. P. Barber, J. Blaine, I. Salloum, and K. Moras. 2003. The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. The American Journal of Psychiatry 160:1320–25. doi:10.1176/appi.ajp.160.7.1320.
   PubMed Web of Science ®Google Scholar
• Woods, J. W., M. Tanen, D. J. Figueroa, C. Biswas, E. Zycband, D. E. Moller, C. P. Austin, and J. P. Berger. 2003. Localization of PPARdelta in murine central nervous system: Expression in oligodendrocytes and neurons. Brain Research 975:10–21. doi:10.1016/S0006-8993(03)02515-0.
   PubMed Web of Science ®Google Scholar
• Wright, N., O. D’Agnone, P. Krajci, R. Littlewood, H. Alho, J. Reimer, C. Roncero, L. Somaini, and I. Maremmani. 2016. Addressing misuse and diversion of opioid substitution medication: Guidance based on systematic evidence review and real-world experience. Journal of Public Health (Oxford) 38 (3):e368–74. doi:10.1093/pubmed/fdv150.
   PubMed Web of Science ®Google Scholar
• Yrjänheikki, J., R. Keinänen, M. Pellikka, T. Hökfelt, and J. Koistinaho. 1998. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proceedings National Academic Sciences USA 95 (26):15769–74.
   PubMed Web of Science ®Google Scholar
• Zhao, M., C. Fan, J. Du, H. Jiang, H. Chen, and H. Sun. 2012. Cue-induced craving and physiological reactions in recently and long-abstinent heroin-dependent patients. Addictive Behaviors 37 (4):393–98. doi:10.1016/j.addbeh.2011.11.030.
   PubMed Web of Science ®Google Scholar
• Zijlstra, F., D. J. Veltman, J. Booij, W. van den Brink, and I. H. Franken. 2009. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug and Alcohol Dependence 99:183–92. doi:10.1016/j.drugalcdep.2008.07.012.
   PubMed Web of Science ®Google Scholar